Abraxane, Nab-Paclitaxel, is Taxol® drug (chemotherapy) link to a protein called Albumin. As a monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Home » Abraxane
Facebook
Twitter
LinkedIn
WhatsApp
Abraxane
To check if our service suits your case
We need to talk
Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.
Article categories
קטגוריות המאמרים
Popular topics
Tags
Alpelisib
Amivantamab
ASCO 2025
ASCO 2026
ASCO Breast Cancer
Biological Drugs
Bispecific Antibody
Breast Cancer
Breast Cancer Clinical Trials
Cancer Drug Development
Cancer Research
CAR T treatments
Chemotherapy
Clinical Trials
Genetic Engineering Treatments
Genomic Testing
Head and Neck Cancer
Immunotherapy
Innovative Cancer Treatments
innowacyjne terapie onkologiczne
Keytruda
leczenie nowotworów mózgu
Medical Cannabis
Metastatic Breast Cancer
Metastatic Head and Neck Cancer
MTAP Deletion
MTAP Loss
nowotwór piersi
Oncology
Palbociclib
PI3K AKT mTOR
PI3K Pathway
PIK3CA Mutation
Precision Oncology
PRMT5 Inhibitor
Progression Free Survival
rak płuca
RAS(ON) Inhibitor
RAS Mutation
Stage 4 Cancer
Targeted Drugs
Targeted Therapy
terapia ADC
Trial-In Pharma
TUXEDO-3






